TY - JOUR
T1 - Circulating Progenitor Cells Are Associated With Bioprosthetic Aortic Valve Deterioration
T2 - A Preliminary Study
AU - Kanaji, Yoshihisa
AU - Ozcan, Ilke
AU - Toya, Takumi
AU - Gulati, Rajiv
AU - Young, Melissa
AU - Kakuta, Tsunekazu
AU - Lerman, Lilach O.
AU - Lerman, Amir
N1 - Publisher Copyright:
© 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2023/1/17
Y1 - 2023/1/17
N2 - BACKGROUND: Mechanisms underlying bioprosthetic valve deterioration are multifactorial and incompletely elucidated. Reparative circulating progenitor cells, and conversely calcification-associated osteocalcin expressing circulating progenitor cells, have been linked to native aortic valve deterioration. However, their role in bioprosthetic valve deterioration remains elu-sive. This study sought to evaluate the contribution of different subpopulations of circulating progenitor cells in bioprosthetic valve deterioration. METHODS AND RESULTS: This single-center prospective study enrolled 121 patients who had peripheral blood mononuclear cells isolated before bioprosthetic aortic valve replacement and had an echocardiographic follow-up ≥2 years after the proce-dure. Using flow cytometry, fresh peripheral blood mononuclear cells were analyzed for the surface markers CD34, CD133, and osteocalcin. Bioprosthetic valve deterioration was evaluated by hemodynamic valve deterioration (HVD) using echocar-diography, which was defined as an elevated mean transprosthetic gradient ≥30 mm Hg or at least moderate intraprosthetic regurgitation. Sixteen patients (13.2%) developed HVD during follow-up for a median of 5.9 years. Patients with HVD showed significantly lower levels of reparative CD34+ CD133+ cells and higher levels of osteocalcin-positive cells than those without HVD (CD34+ CD133+ cells: 125 [80, 210] versus 270 [130, 420], P=0.002; osteocalcin-positive cells: 3060 [523, 5528] versus 670 [180, 1930], P=0.005 respectively). Decreased level of CD34+ CD133+ cells was a significant predictor of HVD (hazard ratio, 0.995 [95% CI, 0.990%– 0.999%]). CONCLUSIONS: Circulating levels of CD34+ CD133+ cells and osteocalcin-positive cells were significantly associated with the subsequent occurrence of HVD in patients undergoing bioprosthetic aortic valve replacement. Circulating progenitor cells might play a vital role in the mechanism, risk stratification, and a potential therapeutic target for patients with bioprosthetic valve deterioration.
AB - BACKGROUND: Mechanisms underlying bioprosthetic valve deterioration are multifactorial and incompletely elucidated. Reparative circulating progenitor cells, and conversely calcification-associated osteocalcin expressing circulating progenitor cells, have been linked to native aortic valve deterioration. However, their role in bioprosthetic valve deterioration remains elu-sive. This study sought to evaluate the contribution of different subpopulations of circulating progenitor cells in bioprosthetic valve deterioration. METHODS AND RESULTS: This single-center prospective study enrolled 121 patients who had peripheral blood mononuclear cells isolated before bioprosthetic aortic valve replacement and had an echocardiographic follow-up ≥2 years after the proce-dure. Using flow cytometry, fresh peripheral blood mononuclear cells were analyzed for the surface markers CD34, CD133, and osteocalcin. Bioprosthetic valve deterioration was evaluated by hemodynamic valve deterioration (HVD) using echocar-diography, which was defined as an elevated mean transprosthetic gradient ≥30 mm Hg or at least moderate intraprosthetic regurgitation. Sixteen patients (13.2%) developed HVD during follow-up for a median of 5.9 years. Patients with HVD showed significantly lower levels of reparative CD34+ CD133+ cells and higher levels of osteocalcin-positive cells than those without HVD (CD34+ CD133+ cells: 125 [80, 210] versus 270 [130, 420], P=0.002; osteocalcin-positive cells: 3060 [523, 5528] versus 670 [180, 1930], P=0.005 respectively). Decreased level of CD34+ CD133+ cells was a significant predictor of HVD (hazard ratio, 0.995 [95% CI, 0.990%– 0.999%]). CONCLUSIONS: Circulating levels of CD34+ CD133+ cells and osteocalcin-positive cells were significantly associated with the subsequent occurrence of HVD in patients undergoing bioprosthetic aortic valve replacement. Circulating progenitor cells might play a vital role in the mechanism, risk stratification, and a potential therapeutic target for patients with bioprosthetic valve deterioration.
KW - aortic valve stenosis
KW - bioprosthetic valve deterioration
KW - circulating progenitor cells
KW - structural valve degeneration
KW - valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85146352901&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146352901&partnerID=8YFLogxK
U2 - 10.1161/jaha.122.027364
DO - 10.1161/jaha.122.027364
M3 - Article
C2 - 36645093
AN - SCOPUS:85146352901
SN - 2047-9980
VL - 12
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 2
M1 - e027364
ER -